By Rob Curran
Lantheus Holdings said an imaging agent designed to identify markers of Alzheimer's disease showed promise in two clinical trials.
The Bedford, Mass., maker of pharmaceuticals with radiological applications said its MK-6240 product candidate met primary end-points in clinical trials assessing its sensitivity and specificity. The company will use the data to support a New Drug Application to the Food and Drug Administration for the imaging agent in the third quarter.
The MK-6240 compound, used in Positron Emission Tomography, targets tau protein aggregation, associated with neurological diseases, including Alzheimer's disease.
"As a clinician, the ability to visualize tau pathology represents the opportunity for a seismic shift in how we diagnose and manage Alzheimer's disease," said Lantheus' medical director, Luca Passamonti.
Write to Rob Curran at rob.curran@wsj.com
(END) Dow Jones Newswires
April 30, 2025 09:02 ET (13:02 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.